Company*
(Symbol)

Product

Description

Indication

Status (Date)


CANCER

Allos Therapeu-
tics
Inc. (ALTH)

RSR13

Synthetic allosteric modifier of hemoglobin that noncovalently binds to hemoglobin, increasing oxygen delivery to hypoxic tissue

Non-small-cell lung cancer

Company updated survival results from a Phase II trial showing a median survival rate of 20.6 months (11/6)

AnorMED Inc.
(Canada; TSE:
AOM)

AMD-3100

Inhibits the binding action of HIV with the CXCR4 chemokine co-receptor

Cancers involving blood and immune systems

Phase I results showed AMD-3100 rapidly mobilizes stem cells out of bone marrow and into the circulatory system (11/7)

Cell Genesys
Inc.
(CEGE)

GVAX

Cancer vaccine; immunotherapeutic comprising irradiated and genetically modified tumor cells that secrete granulocyte macrophage-colony stimulating factor

Acute myelogenous leukemia

Company is initiating a Phase II trial (11/27)

Cell Therapeu-
tics
Inc. (CTIC)

Trisenox (FDA- approved)

Arsenic trioxide

Acute promyelocytic leukemia

Company presented data demonstrating that Trisenox induces durable overall and relapse-free survival (11/7)

Celsion Corp.
(AMEX:CLN)

¿

Uses targeted heat technology delivered by microwave technology

Benign prostatic hyperplasia

Company completed treatment of all 160 patients in the pivotal Phase II trial (11/29)

Dendreon Corp.
(DNDN)

Mylovenge

Cancer vaccine designed to trigger the immune system

Multiple myeloma

Company initiated a Phase II trial (11/6)

EntreMed
Inc.
(ENMD)

Endostatin

Naturally occurring angiogenesis inhibitor

Neuroendocrine tumors

Company began a Phase II trial (11/28)

Genaera Corp.
(GENR)

Squalamine

An angiogenesis inhibitor

Non-small-cell lung cancer

Company began a Phase IIb trial (11/28)

Genta Inc.
(GNTA)

Genasense

Antisense compound geared toward blocking the production Bcl-2

Non-small-cell lung cancer

Genta began a randomized trial designed to compare Genasense plus Aventis Pharma Inc.'s Taxotere compared to Taxotere alone (11/5)

GenVec Inc.
(GNVC)

TNFerade

Delivers the human tumor necrosis factor alpha gene directly to tumors, using GenVec's adenovector gene delivery technology

Cancer

In a clinical study, two of seven patients showed a complete response, two others showed a partial response and three demonstrated stable disease (11/7)

GlycoDesign
Inc.
(Canada;
TSE:GD)

GD0039

Orally administered and blocks the production of specific carbohydrates that are important for cancer spread

Metastatic renal cancer

Company started its expanded Phase II trial (11/26)

ILEX Oncology
Inc.
(ILXO)

Eflornithine

Orally delivered difluoro- methylornithine; selective irreversible inhibitor of ornithine decarboxylase, an enzyme that controls formation of certain polyamines required by dividing cells

Superficial bladder cancer

Company completed patient enrollment for its Phase III trial (11/30)

Immuno-
Designed
Molecules
SA
(France)*

¿

IDM-activated macrophage cells

Bladder cancer

Phase I/II data show the cells significantly reduce tumor recurrence (11/21)

ImmunoGen
Inc.
(IMGN)

huC242-
DM1/SB-
408075

Tumor-activated prodrug

Colorectal, pancreatic and certain non- small-cell lung cancers

Company reported favorable safety data from the initial 27 patients enrolled in a clinical trial (11/1)

Inhale Thera-
peutic
Systems
Inc.
(INHL)

Inhaleable leuprolide

Peptide analogue

Prostate cancer

A 12-person study showed that a powdered formulation of leuprolide developed with Inhale's Inhance pulmonary delivery technology delivered the drug with a bioavailability of 18%, compared to injectable systemic delivery (11/29)

Lorus Thera-
peutics Inc.
(Canada; TSE:
LOR)

Virulizin

Immunotherapeutic drug that leads to stimulation of macrophages, monocytes and natural killer cells to attack tumor cells

Advanced pancreatic cancer

Company initiated a Phase III trial (11/20)

MedImmune
Inc.
(MEDI)

Ethyol (FDA-
approved)

Amifostine

Radiation therapy-induced xerostomia

Phase II data indicated that subcutaenously administered Ethyol may provide comparable protective effects as intravenously administered Ethyol (11/6)

MGI Pharma
Inc.
(MOGN)

Irofulven

Anticancer compound

Pancreatic cancer

Phase II data showed that eight of 22 patients who received more than one course of treatment were alive at six months (11/8)

MGI Pharma
Inc.
(MOGN)

Salagen (FDA- approved)

Tablets; pilocarbine HCl

Head and neck cancer

Clinical data showed that Salagen resulted in statistically significant improvement of salivary flow vs. placebo (11/6)

Millennium
Pharmaceuticals
Inc.
(MLNM)

LDP-341

Small-molecule protease inhibitor

Multiple myeloma

Phase I results in 10 patients showed antitumor activity and manageable side effects (11/2)

NeoPharm Inc.
(NEOL)

IL13-PE38

Tumor-targeting agent

Malignant glioma

Phase I/II results showed that IL13-PE38 may be effective, safe and effectively administered by positive pressure microinfusion (11/19)

Oncolytics
Biotech Inc.
(Canada; TSE:
ONC)

Reolysin

A human reovirus-based product

Cancer

Company completed enrollment for its Phase I trial (11/29)

Onyx Pharma-
ceuticals
Inc.
(ONXX)

BAY 43-9006

Anticancer small-molecule Raf kinase inhibitor

Cancer

Phase I data indicate the compound was well tolerated with few adverse events and no dose-related toxicities (11/1)

OSI Pharma-
ceuticals
Inc.
(OSIP) and
F. Hoffmann-La
Roche Ltd.
(Switzerland)

Tarceva

Epidermal growth factor receptor tyrosine kinase

Non-small-cell lung cancer

Companies initiated a Phase III trial evaluating the use of Tarceva in combination with gemcitabine/cisplatin (11/20)

Pharmacyclics
Inc.
(PCYC)

Xcytrin

Motexafin gadolinium injection

Glioblastoma multiforme

Company said Phase I results suggest the potential utility of Xcytrin in treating glioblastoma multiforme (11/7)

Regeneron
Pharmaceu-
ticals Inc.
(REGN)

VEGF Trap

Vascular Endothelial Growth Factor Trap, an angiogenesis inhibitor

Solid tumor malignancies and non-Hodgkin's lymphoma

Company initiated a Phase I trial (11/28)

Sonus Pharma-
ceuticals
Inc.
(SNUS)

S-8184

A paclitaxel cancer product

Non-small-cell lung cancer

Phase I results showed that one of 16 patients showed a partial tumor response (11/12)

Stressgen Bio-
technologies
Corp.
(Canada;
TSE:SSB)

HspE7

Novel immunothera-
peutic; recombinant fusion product composed of heat shock protein 65 from Mycobacterium bovis BCG and the protein E7

Anal dysplasia

Phase II results demonstrated a 75% reduction to low-grade dysplasia at six months following treatment; at 18 months, 50% were in complete remission (11/29)

SuperGen Inc.
(SUPG)

Decitabine

Inhibits DNA methyl-
transferase activity

Cancer

Phase I data showed encouraging and objective responses in more than half of the patients treated at very low dosages (11/9)

SuperGen Inc.
(SUPG)

Nipent (FDA-
approved)

Pentostatin for injection; chemotherapeutic drug that inhibits adenosine deaminase (blocks DNA synthesis)

Non-Hodgkin's lymphoma and chronic lymphocytic leukemia

Phase II data showed the regimen of Nipent used in combination with rituximab was well tolerated (11/8); Phase I/II data of Nipent in combination with cyclophosphamide showed a 73% response rate in patients with chronic lymphocytic leukemia (11/13); a regimen of Nipent with photophoresis and reduced-dose body irradiation showed an overall response rate of 85% in cancer patients prior to allogeneic bone marrow transplants (11/14)

SuperGen Inc.
(SUPG)

Rubitecan

Oral chemotherapy compound

Cancer

Phase II data showed the drug is active and well tolerated in patients previously treated for advanced gastric adenocarcinoma (11/12)

Supratek
Pharma
Inc.
(Canada)*

SP1049C

Combination of doxorubicin and Supratek's Biotransport carrier technology

Adenocarcinoma of the esophagus

Phase II enrollment is under way (11/15)

CARDIOVASCULAR

Alexion Pharma-
ceuticals Inc.
(ALXN)

Pexelizumab

Anti-inflammatory C5 inhibitor monoclonal antibody fragment

Acute cardiovascular indications

Company plans to begin a Phase III trial (11/13)

Angiogene Inc.*

Beta-Impact

Oliglow radiothera-
peutic compound; Oliglow is a beta- emitter source

Restenosis following balloon angioplasty

Company enrolled the first patients in a Phase I/II trial (11/29)

AtheroGenics
Inc.
(AGIX)

AGI-1067

Oral agent; anti-inflammatory compound with anti-oxidant properties

Restenosis in post-angioplasty patients

Phase II results showed the compound met its primary endpoint (11/12)

Corgentech
Inc.*

E2F Decoy

Oligonucleotide; works to prevent occlusion in grafted veins

Coronary artery bypass surgery

Phase IIb trial demonstrated that E25 Decoy significantly reduced graft failure following coronary artery bypass graft surgery (11/14)

Corvas Inter-
national Inc.
(CVAS) and
Pfizer Inc.

UK-279,276

Neurophil inhibitory factor, or rNIF

Ischemic stroke

Phase IIb enrollment has been completed (11/14)

CV Therapeu-
tics
Inc. (CVTX)

CVT-510

A selective A1 adenosine receptor agonist

Atrial fibrillation

Phase II results showed CVT-510 consistently reduced heart rate from baseline without decreasing blood pressure (11/19)

CV Therapeu-
tics
Inc. (CVTX)

Ranolazine

Part of pFOX (partial fatty acid oxidation) inhibitors

Angina

Phase III results showed the drug met its primary efficacy endpoint with a statistically significant increase in patients' symptom-limited exercise duration compared to placebo (11/14)

Esperion Thera-
peutics
Inc.
(ESPR)

ETC-588

Large unilamellar vesicles

Acute coronary syndromes

Company reported positive preliminary results from a Phase IIa trial (11/27)

GenVec Inc.
(GNVC)

BioBypass

Angiogenic gene therapy that delivers vascular endothelial growth factor 121

Peripheral vascular disease

Phase I results demonstrated that BioBypass was well tolerated with injection site swelling being the only consistently recorded drug-related side effect (11/13)

Hemosol Inc.
(Canada; HMSL;
TSE:HML)

Hemolink

Oxygen therapeutic; a red-blood cell substitute

Primary cardiac bypass grafting surgery

Company received approval to begin a clinical trial with 180 patients in the U.S. and the UK (11/26)

La Jolla Pharma-
ceutical Co.
(LJPC)

LJP 1082

Composed of four copies of a recombinant protein attached to a synthetic organic platform designed to reduce disease-causing antibodies

Stroke, deep- vein thrombosis and other conditions

Company initiated a Phase I/II trial (11/8)

Valentis Inc.
(VLTS)

VEGF165

Gene delivered with Valentis' lipid delivery system

Peripheral arterial disease

Phase II results showed VEGF165 can induce angiogenesis in the legs of patients; also, the safety issues associated with adenoviral vectors were not seen in patients receiving the gene delivered with the system (11/14)

CENTRAL NERVOUS SYSTEM

Durect Corp.
(DRRX)

Chronogesic

A three-month continuous infusion subcutaneous implant

Chronic pain

Company began a Phase III trial (11/1)

Interferon
Sciences Inc.
(OTC BB:IFSC)

Alferon N & Betaseron

Interferon alfa-n3 and interferon beta-1b

Multiple sclerosis

Data showed a reduction in the volume of T2-weighted MS brain lesions in both treatment groups as compared to increased lesion volume in the untreated control group (11/8)

Nastech Pharma-
ceutical Company
Inc.
(NSTK)

Interferon beta

Nasally administered

Multiple sclerosis

Company began a Phase I U.S. trial (11/28)

DIABETES

Centocor Inc.
(unit of Johnson
& Johnson) and
Eli Lilly & Co.

ReoPro

Abciximab, an anticlotting agent

Diabetes patients undergoing angioplasty

Follow-up trial data indicate that ReoPro-treated patients were less likely to die during the six months following the procedure; they also fared better when looking at the combined endpoint of death, recurrence of heart attack and any urgent procedures to open coronary arteries (11/12)

Ortec Interna-
tional
Inc.
(ORTC)

OrCel

A collagen sponge seeded with allogeneic epidermal and dermal cells

Diabetic ulcers

Data showed a greater than 100% improvement over standard care with a twice-as-fast rate of healing for the Orcel-treated group (11/13)

Theratechnol-
ogies
Inc.
(Canada; TSE:TH)

ThGRF (TH 9507)

Growth hormone-releasing factor analogue

Type II diabetes

Company plans to initiate a Phase II trial to evaluate the safety of two doses (11/20)

INFECTION

Agouron
Pharmaceu-
ticals
Inc. (unit
of Pfizer Inc.)

Viracept (FDA- approved)

Nelfinavir myselate;
HIV protease inhibitor

HIV

Data on the long-term extension phase of the pivotal study of Viracept in combination with AZT and 3TC showed that the majority of patients maintained antiretroviral activity and achieved replenishment of CD4 lymphocytes (11/5)

Amerimmune
Pharmaceu-
ticals
Inc. (OTC
BB:AMUN)

Cytolin

Intravenous formulation of a murine monoclonal antibody

HIV/AIDS

Company completed a Phase Ia trial that showed Cytolin was safe and well tolerated (11/29)

Antex Bio-
logics Inc.
(AMEX:ANX)

Helivax

Oral vaccine

Gastrointestinal infections and disease caused by Helicobacter pylori

A Phase Ib trial showed volunteers were positive for immune cell proliferation, cytokine production and secretory IgA antibodies (11/9)

Antigenics
Inc.
(AGEN)

AG-702

Recombinant vaccine using Antigenics' heat shock protein technology

Genital herpes

Company initiated a Phase I trial (11/7)

BioMarin
Pharmaceutical
Inc.
(BMRN)
and Genzyme
General
(GENZ)

Aldurazyme

Enzyme replacement therapy

Mucopoly-
saccharidosis I

Phase III results were positive, and the company plans to file regulatory applications early next year (11/2)

Chiron Corp.
(CHIR)

Tifacogin

Recombinant form of tissue factor pathway inhibitor, thought to block tissue-factor-mediated clotting in small blood vessels

Sepsis

Tifacogin did not meet its primary endpoint of reducing 28-day all-cause mortality in a Phase III trial (11/21)

CV Technologies Inc. (Canada;
CDNX:CVQ)

CVT-E002

A multicomponent phytopharmaceutical

Acute viral respiratory illness

Phase II results were positive showing that 1% of the treated group, compared to 7% of the placebo group, got influenza illness; and 1% of the treated group, compared to 9% of the placebo group, got influenza or syncytial virus illness (11/30)

Enzo Biochem
Inc.
(NYSE:
ENZ)

EHT899

Orally available viral protein

Hepatitis B

Phase II results showed a dramatic improvement in key liver necroinflammatory scores, with 33% of the subjects showing improvement (11/12)

Gilead Sciences
Inc.
(GILD)

Adefovir
dipivoxil

Reverse transcriptase inhibitor

Hepatitis B and liver disease

Phase II data of patients receiving the monotherapy and those receiving a combination therapy with lamivudine exhibited a time-wighted average decrease in serum HBV DNA from baseline (11/9); Phase III data demonstrated adefovir dipivoxil 10 mg significantly improved liver function and reduced levels of virus in patients with chronic hepatitis B virus infection (11/12)

Hollis-Eden
Pharmaceu-
ticals
Inc.
(HEPH)

HE2000

Immune regulating hormone

HIV

Data indicated that treatment significantly reduced elevated levels of a number of well-known inflammatory mediators throughout the five-month treatment period (11/8)

InterMune Inc.
(ITMN)

Infergen

Interferon alfacon-1

Hepatitis C

Company released positive results from a Phase IV trial comparing the use of Infergen plus ribavirin to the use of interferon alfa-2b plus ribavirin; patients treated with Infergen and ribavirin achieved a sustained virologic response of 56% (11/12)

Maxim Pharma-
ceuticals
Inc.
(MAXM)

Ceplene

Histamine
dihydrochloride

Hepatitis C

Pilot study results of Ceplene in combination with interferon-alpha and ribavirin showed a sustained complete viral response in 38% of evaluable patients (11/12)

Oxxon
Pharmaccines
(UK)*

¿

Vaccine

Hepatitis B

Company entered Phase I trials with the vaccine (11/7**)

Ribozyme
Pharmaceu-
ticals
Inc.
(RZYM)

Heptazyme

Anti-hepatitis C and hepatitis B ribozyme

Hepatitis C and hepatitis B

Phase I results demonstrated that Heptazyme was well tolerated and was efficiently absorbed after subcutaneous administration (11/13)

Stressgen
Biotechnologies
Corp.
(Canada; TSE:SSB)

HspE7

Novel immunothera-
peutic; recombinant fusion product composed of heat shock protein 65 from Mycobacterium bovis BCG and the protein E7

Recurrent respiratory papillomatosis

Company initiated a Phase II trial in pediatric patients who require frequent surgery (11/19)

Triangle Pharm-
aceuticals Inc.
(VIRS)

Coviracil

A cytosine nucleoside analogue

Hepatitis B

Coviracil was well tolerated at all doses in a Phase I trial (11/13)

Trimeris Inc.
(TRMS) and
Hoffmann-La
Roche Inc.

T20-305

T20 in combination with oral antiretrovirals

HIV

Companies are initiating patient enrollment in a U.S. study involving 450 adults (11/7)

Versicor Inc.
(VERS)

Dalbavancin

Once-weekly treatment; a novel second-generation glycopeptide agent

Staphylococcal and other Gram-positive hospital infections

Phase I results showed that daily and weekly dosing are well tolerated; a Phase II study is under way (11/28)

Vical Inc.
(VICL)

MuStDO 5

Multigene vaccine incorporating five genes for Plasmodium falciparum antigens plus a naked DNA agent encoding granulocyte macrophage-colony stimulating factor, an immune stimulant

Malaria

Vical completed an initial Phase II trial (11/13)

ViroPharma
Inc.
(VPHM)
and Wyeth-Ayerst
Laboratories

VP 50406

Chemical compound

Hepatitis C

The compound failed to show the desired level of antiviral activity in Phase IIa trials, causing the companies to stop development (11/12)

MISCELLANEOUS

Alexion Phar-
maceuticals
Inc.
(ALXN)

5G1.1

Humanized monoclonal antibody C5 complement inhibitor

Rheumatoid arthritis

Phase II data showed the drug met its primary endpoint in one of the treatment groups after three months of treatment (11/14)

Alteon Inc.
(AMEX:ALT)

ALT-711

A.G.E. Crosslink
Breaker

End-stage renal disease

Company began a Phase I trial (11/7)

Amgen Inc.
(AMGN)

Kineret

Anakinra; interleukin-1 receptor antagonist

Arthritis

Phase II results with 1,414 patients showed that, at the end of six months, the most frequent adverse event was a mild to moderate reaction at the injection site; results from other Phase II/III studies showed Kineret improved quality of life for patients (11/12)

Angiotech
Pharmaceu-
ticals
Inc.
(Canada;
TSE:ANP)

Paxceed

Systemic formulation of micellar paclitaxel

Psoriasis

Phase II results showed five patients experienced a 50% to 75% improvement in disease severity when treated over six months with monthly intravenous infusions (11/19)

AVI Bio-
Pharma
Inc.
(AVII)

AVI-4557

Third-generation Neugene antisense compound that targets the liver enzyme, cytochrome P450, responsible for drug metabolism

To keep drugs in their active forms longer and to decrease their toxicities

Company completed collection of data for its Phase I trial; data indicated no drug-related toxicity or safety issues (11/6)

Cambridge
Antibody
Technology
Group plc
(UK;
LSE:CAT) and
Genzyme
General
(GENZ)

CAT-192

Human anti-TGF_ monoclonal antibody

Diffuse systemic sclerosis

Companies initiated a Phase I/II trial (11/12)

Cellegy Phar-
maceuticals
Inc.
(CLGY)

Tostrex

A transdermal testosterone gel

Hypogonadism

Cellegy completed enrollment into an ongoing Phase III trial (11/6)

Centocor
Inc.
(unit of
Johnson &
Johnson)

Remicade
(FDA-
approved)

Infliximab; a monoclonal antibody that specifically targets and irreversibly binds to TNF-alpha on the cell membrane in the blood

Active spondy-
loarthropathy

A study with 40 patients showed that at 12 weeks, patient and physician global assessment improved in the infliximab group, while no improvements were seen in placebo patients (11/13)

Connetics
Corp.
(CNCT)

OLUX

Clobetasol proprionate foam 0.05%; super-high potency corticosteroid

Dermatoses

Phase IV results showed that patients experienced a statistically significant improvement compared to placebo (11/5)

Corporate
Technology
Development
Inc.*

orBec

Oral dual-release formulation of beclo- methasone dipropionate

Crohn's disease

Company initiated a Phase II trial (11/1)

CytRx Corp.
(CYTR)

CRL-5861

Purified poloxamer 188

Acute sickle cell crisis

Phase III data showed that CRL-5861 shortened the duration of the painful crisis episodes commonly experienced by sickle cell patients (11/7)

Emisphere
Technol-
ogies
Inc.
(EMIS)

Cromolyn
sodium

A nonsteroidal anti-allergy medication delivered with an Emisphere carrier in an oral capsule formulation

Allergies

Phase I results showed effective absorption from the gastrointestinal tract (11/29)

Genmab
A/S
(Denmark;
CSE:GEN)

HuMax-CD4

Fully human antibody

Psoriasis

Phase II results showed a statistically significant dose response in doses up to 160 mg; the drug was safe and well tolerated (11/12)

Hollis-Eden
Pharmaceu-
ticals
Inc.
(HEPH)

HE2200

Immune-regulating hormone drug candidate

Immune dysregulation diseases, such as inflammatory bowel disease

Company completed a Phase I study with subcutaneously administered HE2200 (11/26)

Human
Genome
Sciences Inc.
(HGSI)

Lympho-
Stat-B

Human monoclonal antibody targeting BLyS

Systemic lupus erythematosus and other autoimmune diseases

The company is proceeding with a Phase I trial (11/1); clinical data showed positive results in patients with inflammatory arthritis and those with osteoarthritis or traumatic arthritis, and Sjogren's syndrome (11/14)

ICOS Corp.
(ICOS)

IC485

PDE4 inhibitor

Inflammatory conditions

Company initiated a Phase I trial (11/5)

Immunex
Corp.
(IMNX)

Enbrel
(FDA-
approved)

Tumor necrosis factor-inhibiting drug

Ankylosing spondylitis

Phase II results showed that 80% of 20 patients reached the composite endpoint of improvement (11/12)

Immunex
Corp.
(IMNX)

Enbrel
(FDA-
approved)

Tumor necrosis factor-inhibiting drug

Psoriatic arthritis

Phase III results showed 59% of 101 patients receiving Enbrel achieved an ACR20 response compared to 15% of 104 patients receiving placebo (11/12)

IntraBiotics
Pharmaceu-
ticals
Inc.
(IBPI)

Iseganan

Antibiotic; oral solution

Oral mucositis

Company began enrollment in the final Phase III trial of its antibiotic to prevent and treat oral mucositis in chemotherapy patients (11/7)

Isis Pharma-
ceuticals
Inc.
(ISIP)

ISIS
2302

Antisense inhibitor of intercellular adhesion molecule-1

Crohn's disease

Company initiated a Phase III trial after examining the failed Phase IIb trial and tweaking a dosing scheme (11/29)

Isis Pharma-
ceuticals
Inc.
(ISIP)

Isis
104838

Antisense inhibitor of tumor necrosis factor-alpha

Rheumatoid arthritis

Company initiated clinical testing (11/19)

La Jolla
Pharmaceu-
tical
Co.
(LJPC)

LJP 394

Molecule (toleragen) that binds to the surface of B cells and shuts off production of antibodies to double-stranded DNA

Lupus renal disease

Phase II/III results indicated that treatment with LJP 394 appeared to be as effective as current immunosuppressive therapy in reducing antibodies to double-stranded DNA (11/14)

Micrologix
Biotech Inc.
(Canada;
TSE:MBI)

MBI
594AN

Topical drug; bactolysin compound (cationic peptide)

Acne

Phase II preliminary results of 75 patients showed a 32% total acne reduction; study was conducted in the U.S. (11/30)

Millennium
Pharmaceu-
ticals Inc.
(MLNM)
and Abbott
Laboratories
Inc.

MLN
4760

Molecule that inhibits a novel carboxypeptidase enzyme

Metabolic disorders

Companies initiated a Phase I trial (11/27)

Neurocrine
Biosciences
Inc.
(NBIX)

NBI-
34060

A non-benzodiazepine compound that acts against chronic insomnia through a specific site of the GABA-A receptor

Chronic insomnia

Company began a Phase III trial with 500 patients (11/16)

NexMed Inc.
(NEXM)

Alprox-TD

Cream that combines alprostadil and NexACT transdermal delivery technology

Erectile dysfunction

Company conducted two U.S. Phase II studies in which 83% of patients reported satisfaction with treatment (11/1); company initiated two Phase III trials (11/13)

NPS Pharma-
ceuticals
Inc.
(NPSP)

ALX1-11

Full-length human parathyroid hormone

Osteoporosis

Company will expand patient enrollment in the Phase III study, and plans to begin a new study in women receiving hormone replacement therapy (11/26)

Pharmacia
Corp.
(NYSE:
PHA) and
Celltech Group
plc
(UK; NYSE:
CLL; LSE:CCH)

CDP870

Humanized, pegylated TNF-alpha inhibitor

Rheumatoid arthritis

Phase II results indicated that higher doses appeared to lead to better results (11/12)

Protein
Design
Labs
Inc.
(PDLI)

SMART Anti-
Gamma

Interferon antibody

Crohn's disease

Company released promising preliminary results from an ongoing Phase I/II trial (11/5)

Protein
Design
Labs
Inc.
(PDLI)

Zenapax

Humanized antibody

Asthma

Company initiated a Phase II trial (11/27)

Regeneron
Pharmaceu-
ticals
Inc.
(REGN)

Interleukin-1 Cytokine Trap

Antagonist that mimics the body's natural receptors

Rheumatoid arthritis

Preliminary Phase I results show the IL-1 Trap was generally well tolerated and displayed a favorable safety profile (11/14)

Scil Bio-
medicals
GmbH
(Germany)*

SMART
Anti-L-
Selectin

Humanized compound

Psoriasis

Company initiated a Phase Ib trial (11/5)

Vivus Inc.
(VVUS)

Alista

Topical formulation of alprostadil

Female sexual dysfunction

Company saw positive results from a Phase II study (11/29)


Notes:

* Privately held

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange

No Comments